Modern Possibilities of Using Acotiamide in the Treatment of Functional Dyspepsia
https://doi.org/10.22416/1382-4376-2024-34-1-70-75
Abstract
Aim: to evaluate the efficacy and safety of the new prokinetic drug acotiamide in the treatment of functional dyspepsia.
Key findings. Acotiamide is an antagonist of inhibitory muscarinic receptors of type 1 and 2 and a reversible inhibitor of acetylcholinesterase activity. In patients with functional dyspepsia acotiamide normalizes the accommodation of the fundal part of the stomach and accelerates delayed gastric emptying. The conducted studies have confirmed the higher efficacy of acotiamide compared to placebo in reducing the severity of such symptoms of functional dyspepsia as a feeling of epigastric postprandial fullness and bloating, early satiation. The advantage of acotiamide in comparison to other prokinetics (in particular, metoclopramide and domperidone) is the high safety of use and the absence of influence on the duration of the Q-T interval.
Conclusion. The high efficacy and safety of the application makes it advisable to use acotiamide in the treatment of patients with functional dyspepsia.
About the Authors
A. A. Sheptulin
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Arkadiy A. Sheptulin — Dr. Sci. (Med.), Professor at the Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine
119435, Moscow, Pogodinskaya str., 1, build. 1
Yu. S. Rabotyagova
Medical Institute named after G.I. Georgievsky of V.I. Vernadsky Crimean Federal University
Yulia S. Rabotyagova — Cand. Sci. (Med.), Teaching Assistant at the Department of Therapy, Gastroenterology, Cardiology and General Medical Practice (Family Medicine)
295006, Simferopol, Lenina blvrd, 5/7
References
1. Stanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., et al. Gastroduodenal disorders. Gastroenterology. 2016;150(6):1380–92. DOI: 10.1053/j.gastro.2016.02.011
2. Aziz A., Palsson O.S., Törnblom H., Sperber A.D., Whitehead W.E., Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: A cross-sectional population-based study. Lancet Gastroenterol Hepatol. 2018;3(4):252–62. DOI: 10.1016/S2468-1253(18)30003-7
3. Ivashkin V.T., Sheptulin A.A., Kiprianis B.A. Functional dyspepsia. Moscow: MEDpress-inform, 2017. (In Russ.).
4. D oi Y., Murasaki O., Kaibara M., Uezono Y., Hayashi H., Yano K., et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur J Pharmacol. 2004;505(1–3):31–5. DOI: 10.1016/j.ejphar.2004.10.003
5. Matsunaga Y., Tanaka T., Yoshinaga K., Ueki S., Hori Y., Eta R., et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: Comparison with cisapride, itopride, and mosapride. J Pharmacol Exp Ther. 2011;336(3):791–800. DOI: 10.1124/jpet.110.174847
6. Vandenberghe A., Schol J., Van den Houte K., Masuy I., Carbone F., Tack J. Current and emerging therapeutic options for the management of functional dyspepsia. Expert Opin Pharmacother. 2020;21(3):365–76. DOI: 10.1080/14656566.2019.1707805
7. Sun Y., Song G., McCallum R.W. Evaluation of acotiamide for the treatment of functional dyspepsia. Expert Opin Drug Metab Toxicol. 2014;10(8):1161–8. DOI: 10.1517/17425255.2014.920320
8. Kusunoki H., Haruma K., Manabe N., Imamura H., Kamada T., Shiotani A., et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: Randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540–5. DOI: 10.1111/j.1365-2982.2012.01897.x
9. Nakamura K., Tomita T., Tadayuki O., Asano H., Yamasaki T., Okugawa T., et al. A double-blind placebo controlled study of acotiamide hydrochloride for efficacy on gastrointestinal motility of patients with functional dyspepsia. J Gastroenterol. 2017;52(5):602–10. DOI: 10.1007/s00535-016-1260-7
10. Kaai M., Inamori M., Matsuura M., Iwata Y., Iida H., Fujita K., et al. Early effects of acotiamide or mosapride intake on gastric emptying: A randomized 3-way crossover study using the 13C breath test. J Clin Biohem Nutr. 2021;68(3):264–7. DOI: 10.3164/jcbn.20-162
11. Zai H., Matsueda K., Kusano M., Urita Y., Saito Y., Kato H. Effect of acotiamide on gastric emptying in healthy adult humans. Eur J Clin Invest. 2014;44(12):1215–21. DOI: 10.1111/eci.12367
12. Matsueda K., Hongo M., Tack J., Saito Y., Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821–8. DOI: 10.1136/gutjnl-2011-301454
13. Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Kawarai Lefor A., Yamamoto H. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63(3–4):230–5. DOI: 10.2152/jmi.63.230
14. Porika S., Veliganda K.C., Muni S.K., Acharya S., Mehta S.C., Sharma A.D. Real-world, non-interventional, observational study to evaluate effectiveness and tolerability of acotiamide hydrochloride hydrate in treatment of functional dyspepsia. Adv Ther. 2018;35(11):1884–93. DOI: 10.1007/s12325-018-0814-x
15. Matsueda K., Hongo M., Tack J., Aoki H., Saito Y., Kato H. Clinical trial: Dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia – 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618–e173. DOI: 10.1111/j.1365-2982.2009.01449.x
16. Xiao G., Xie X., Fan J., Deng J., Tan S., Zhu Y., et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: Systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:541950. DOI: 10.1155/2014/541950
17. Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Kobayashi Y., Miura Y., et al. Timing and predictors of recurrence of dyspepsia symptoms after cessation of acotiamide therapy for functional dyspepsia: A long-term observational study. Digestion. 2020;101(4):382–90. DOI: 10.1159/000500134
18. Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Miura Y., Kawarai Lefor A., et al. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis. 2017;26(4):345–50. DOI: 10.15403/jgld.2014.1121.264.ski
19. Muta K., Ihara E., Fukaura K., Tsuchida O., Ochiai T., Nakamura K. Effects of acotiamide on the esophageal motility function in patients with esophageal motility disorders: A pilot study. Digestion. 2016;94(1):9–16. DOI: 10.1159/000447010
20. Funaki Y., Ogasavara N., Kawamura Y., Yoshimine T., Tamura Y., Izawa S., et al. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study. Neurogastroenterol Motil. 2020;32(2):e13749. DOI: 10.1111/nmo.13749
21. Yamawaki H., Futagami S., Kawagoe T., Maruki Y., Hashimot S., Nagoya H., et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037–47. DOI: 10.1111/nmo.12805
22. Mayanagi S., Kishino M., Kitagawa Y., Sunamura M. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy. Tohoku J Exp Med. 2014;234(3):237– 40. DOI: 10.1620/tjem.234.237
23. Takeuchi T., Takahashi Y., Kawaguchi S., Ota K., Harada S., Kojima Y., et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol. 2018;33(3):623–30. DOI: 10.1111/jgh.13970
24. Hojo M., Nagahara A., Asaoka D., Takeda T., Izumi K., Matsumoto K., et al. A randomized, double-blind, pilot study of the effect of famotidine on acotiamide treatment for functional dyspepsia. Digestion. 2017;96(1):5–12. DOI: 10.1159/000477345
25. Sinha S., Chary S., Thakur P., Talluri L., Reddy M., Mohan J.M., et al. Efficacy and safety of acotiamide versus mosapride in patients with functional dyspepsia associated with meal-induced postprandial distress syndrome: A phase III randomized clinical trial. Cureus. 2021;13(9):e18109. DOI: 10.7759/cureus.18109
26. Yang Y.J., Bang C.S., Baik G.H., Park T.Y., Shin S.P., Suk K.T., et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol. 2017;17(1):83. DOI: 10.1186/s12876-017-0639-0
27. Giudicessi J.R., Ackerman M.J., Camilleri M. Cardiovascular safety of prokinetic agents: A focus on drug-induced arrhythmias. Neurogastroenterol Motil. 2018;30(6):e13302. DOI: 10.1111/nmo.13302
28. Shrestha D.B., Budhathoki P., Subedi P., Rhadka M., Rarki P., Sedhai Y.R., et al. Acotiamide and functional dyspepsia: A systematic review and meta-analysis. Cureus. 2021;13(12):e20532. DOI: 10.7759/cureus.20532
29. Mizukami K., Katsuta M., Okamoto K., Fukuda K., Ogawa R., Kawahara Y., et al. Influence of acotiamide on 13C-urea breath test for Helicobacter pylori diagnosis. J Clin Biochem Nutr. 2020;67(3):332–7. DOI: 10.3164/jcbn.20-17
30. Miwa H., Nagahara A., Asakawa A., Arai M., Oshima T., Kasugai K., et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47–61. DOI: 10.1007/s00535-021-01843-7
31. Black C.J., Paine P.A., Agrawal A., Aziz I., Eugenicos M.P., Houghton L.A., et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697–723. DOI: 10.1136/gutjnl-2022-327737
32. Ivashkin V.T., Maev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., et al. Diagnosis and treatment of the functional dyspepsia: Clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61. (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-50-61
Review
For citations:
Sheptulin A.A., Rabotyagova Yu.S. Modern Possibilities of Using Acotiamide in the Treatment of Functional Dyspepsia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(1):70-75. https://doi.org/10.22416/1382-4376-2024-34-1-70-75
Views:
1736
Email this article 
